

29 May 2025

Results of General Meeting

EVE Health Group (ASX:EVE, EVE or the Company), confirms that all resolutions put to shareholders at the General Meeting held today, 29 May 2025, were passed by way of a poll.

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, details of the proxy votes received and the poll results for each resolution are attached.

Subject to completion of the proposed acquisition of Nextract Pty Ltd ("Nextract"), the Company also advises that Mr Stuart Gunzburg will be appointed to the Board of EVE as the nominee director of the Nextract vendor shareholders. This represents a change from the originally proposed nominee, Mr Damian Wood.

Mr Wood will instead take on the role of Chief Executive Officer of EVE upon completion of the transaction and following the conclusion of his current contractual commitments. The Board looks forward to working with both Mr Gunzburg and Mr Wood as the Company moves forward with the integration of Nextract and expansion into regulated pharmaceutical markets.

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health and wellness company combining natural health products with advanced pharmaceutical and nutraceutical delivery technologies. Through its brands including Meluka Australia and Nextract, EVE develops and commercialises innovative products supported by regulatory expertise, scientific formulation, and a commitment to consumer wellbeing.

EVE's product portfolio spans functional foods, probiotic concentrates, and reformulated pharmaceutical actives, targeting both retail and pharmacy channels in high-growth markets across Australia, Asia Pacific, and North America. The Group is focused on delivering effective, sustainable health solutions that create value for consumers, shareholders, and the broader community.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

Resolutions voted on at the meeting		Proxies received				If decided by poll				
Resolution	Result	For	Against	Abstain	Discretion	Voted for		Voted against		Abstained
		Number	Number	Number	Number	Number	%	Number	%	Number
Resolution 1 – Approval to a Change in the Nature of the Main Undertaking	Passed by poll	2,014,687,776	1,648,000	1,136,501	5,000,000	2,019,687,776	99.92	1,648,000	0.08	1,136,501
Resolution 2 – Approval of Consolidation of Capital	Passed by poll	2,003,538,852	15,886,925	2,886,500	160,000	2,003,698,852	99.21	15,886,925	0.79	2,886,500
Resolution 3 – Approval to Issue Placement Shares to Unrelated Parties	Passed by poll	1,999,251,024	18,432,751	4,441,002	347,500	1,999,598,524	99.09	18,432,751	0.91	4,441,002
Resolution 4 – Approval to Issue Shares to Nexttract Vendors	Passed by poll	1,999,992,524	16,871,003	5,298,750	310,000	2,000,302,524	99.16	16,871,003	0.84	5,298,750
Resolution 5 – Approval to Issue Lead Manager Shares	Passed by poll	1,996,721,024	19,802,253	3,509,000	2,440,000	1,999,161,024	99.02	19,802,253	0.98	3,509,000